• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种将生物识别标签附加到内源性突变 Kras 等位基因末端的简便方法。

A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.

机构信息

Drexel University College of Medicine, Philadelphia, PA, USA.

Fox Chase Cancer Center, Philadelphia, PA, USA.

出版信息

Methods Mol Biol. 2024;2797:351-362. doi: 10.1007/978-1-0716-3822-4_25.

DOI:10.1007/978-1-0716-3822-4_25
PMID:38570472
Abstract

KRAS mutations occur in approximately ~50% of colorectal cancers (CRCs) and are associated with poor prognosis and resistance to therapy. While these most common mutations found at amino acids G12, G13, Q61, and A146 have long been considered oncogenic drivers of CRC, emerging clinical data suggest that each mutation may possess different biological functions, resulting in varying consequences in oncogenesis. Currently, the mechanistic underpinnings associated with each allelic variation remain unclear. Elucidating the unique effectors of each KRAS mutant could both increase the understanding of KRAS biology and provide a basis for allele-specific therapeutic opportunities. Biotinylation identification (BioID) is a method to label and identify proteins located in proximity of a protein of interest. These proteins are captured through the strong interaction between the biotin label and streptavidin bead and subsequently identified by mass spectrometry. Here, we developed a protocol using CRISPR-mediated gene editing to generate endogenous BioID-tagged Kras and Kras isogenic murine colon epithelial cell lines to identify unique protein proximity partners by BioID.

摘要

KRAS 突变约发生于 50%的结直肠癌(CRC)中,与不良预后和治疗耐药相关。虽然最常见的突变发生在氨基酸 G12、G13、Q61 和 A146,但长期以来一直被认为是 CRC 的致癌驱动因素,新兴的临床数据表明,每种突变可能具有不同的生物学功能,从而导致致癌作用的不同后果。目前,与每种等位基因变异相关的机制基础仍不清楚。阐明每个 KRAS 突变体的独特效应因子既能增加对 KRAS 生物学的理解,又能为等位基因特异性治疗机会提供基础。生物素标记鉴定(BioID)是一种标记和鉴定与感兴趣的蛋白质接近的蛋白质的方法。这些蛋白质通过生物素标记和链霉亲和素珠之间的强相互作用被捕获,然后通过质谱法进行鉴定。在这里,我们开发了一种使用 CRISPR 介导的基因编辑来生成内源性 BioID 标记的 Kras 和 Kras 同基因鼠结肠上皮细胞系的方案,通过 BioID 来鉴定独特的蛋白质邻近伙伴。

相似文献

1
A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.一种将生物识别标签附加到内源性突变 Kras 等位基因末端的简便方法。
Methods Mol Biol. 2024;2797:351-362. doi: 10.1007/978-1-0716-3822-4_25.
2
A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.一种在同基因细胞背景下构建突变 Kras 等位基因的简便方法。
Methods Mol Biol. 2021;2262:323-334. doi: 10.1007/978-1-0716-1190-6_20.
3
A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases.A146 突变与结直肠癌肝转移患者的不同临床行为相关。
JCO Precis Oncol. 2021 Nov 17;5. doi: 10.1200/PO.21.00223. eCollection 2021.
4
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.致癌性 KRAS 通过 RSK1/NF1 途径抑制胰腺癌中的野生型 RAS 信号。
Proc Natl Acad Sci U S A. 2021 May 25;118(21). doi: 10.1073/pnas.2016904118.
5
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation.在结直肠腺瘤形成过程中,KRAS突变对ACSS2的选择性需求。
Res Sq. 2024 Feb 22:rs.3.rs-3931415. doi: 10.21203/rs.3.rs-3931415/v1.
6
AirID, a novel proximity biotinylation enzyme, for analysis of protein-protein interactions.空气 ID,一种新型的临近生物素化酶,用于分析蛋白质-蛋白质相互作用。
Elife. 2020 May 11;9:e54983. doi: 10.7554/eLife.54983.
7
In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.在突变型 KRAS 的结直肠癌细胞中,SLC25A22 介导的谷氨酰胺分解作用降低 DNA 去甲基化以增加 WNT 信号、干性和耐药性。
Gastroenterology. 2020 Dec;159(6):2163-2180.e6. doi: 10.1053/j.gastro.2020.08.016. Epub 2020 Aug 16.
8
4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.4-乙酰基-安石榴苷 B 通过调节 Ras/Raf/miR-193a-3p 信号轴改善西妥昔单抗对 Kras 突变型和野生型结直肠癌的增敏作用。
Int J Mol Sci. 2021 Jul 14;22(14):7508. doi: 10.3390/ijms22147508.
9
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.人类癌症中exon 4 KRAS 突变的基因组和生物学特征。
Cancer Res. 2010 Jul 15;70(14):5901-11. doi: 10.1158/0008-5472.CAN-10-0192. Epub 2010 Jun 22.
10
Selective targeting of the oncogenic G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression.CRISPR/Cas9 靶向致癌 G12S 突变等位基因可诱导有效的肿瘤消退。
Theranostics. 2020 Apr 6;10(11):5137-5153. doi: 10.7150/thno.42325. eCollection 2020.

引用本文的文献

1
Mass Spectrometry-Based Proteomics Technologies to Define Endogenous Protein-Protein Interactions and Their Applications to Cancer and Viral Infectious Diseases.基于质谱的蛋白质组学技术用于定义内源性蛋白质-蛋白质相互作用及其在癌症和病毒感染性疾病中的应用
Mass Spectrom Rev. 2025 Feb 9. doi: 10.1002/mas.21926.

本文引用的文献

1
A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.一种在同基因细胞背景下构建突变 Kras 等位基因的简便方法。
Methods Mol Biol. 2021;2262:323-334. doi: 10.1007/978-1-0716-1190-6_20.
2
Using BioID to Characterize the RAS Interactome.使用 BioID 技术鉴定 RAS 相互作用组。
Methods Mol Biol. 2021;2262:271-280. doi: 10.1007/978-1-0716-1190-6_16.
3
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.老年和年轻患者结直肠癌中 RAS 突变的全面特征分析。
Nat Commun. 2019 Aug 19;10(1):3722. doi: 10.1038/s41467-019-11530-0.
4
BioID as a Tool for Protein-Proximity Labeling in Living Cells.生物识别技术作为活细胞中蛋白质邻近标记的一种工具。
Methods Mol Biol. 2019;2012:299-313. doi: 10.1007/978-1-4939-9546-2_15.
5
Efficient proximity labeling in living cells and organisms with TurboID.TurboID 实现活细胞和生物体内高效的邻近标记。
Nat Biotechnol. 2018 Oct;36(9):880-887. doi: 10.1038/nbt.4201. Epub 2018 Aug 20.
6
KRAS Alleles: The Devil Is in the Detail.KRAS 等位基因:细节决定成败。
Trends Cancer. 2017 Oct;3(10):686-697. doi: 10.1016/j.trecan.2017.08.006. Epub 2017 Sep 12.
7
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.从10000例患者的前瞻性临床测序中揭示的转移性癌症的突变图谱。
Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8.
8
Marker-free coselection for CRISPR-driven genome editing in human cells.无标记共选择用于人类细胞中的 CRISPR 驱动基因组编辑。
Nat Methods. 2017 Jun;14(6):615-620. doi: 10.1038/nmeth.4265. Epub 2017 Apr 17.
9
An improved smaller biotin ligase for BioID proximity labeling.一种用于BioID邻近标记的改良型小型生物素连接酶。
Mol Biol Cell. 2016 Apr 15;27(8):1188-96. doi: 10.1091/mbc.E15-12-0844. Epub 2016 Feb 24.